Federated Hermes Inc. Sells 561,851 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

Federated Hermes Inc. cut its position in SIGA Technologies, Inc. (NASDAQ:SIGA) by 35.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,014,734 shares of the company’s stock after selling 561,851 shares during the quarter. Federated Hermes Inc. owned approximately 1.43% of SIGA Technologies worth $7,702,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale bought a new position in SIGA Technologies in the second quarter worth about $40,000. Steward Partners Investment Solutions LLC bought a new position in SIGA Technologies in the fourth quarter worth about $58,000. Bayesian Capital Management LP bought a new position in SIGA Technologies in the first quarter worth about $97,000. Lazard Asset Management LLC bought a new position in SIGA Technologies in the first quarter worth about $105,000. Finally, EntryPoint Capital LLC acquired a new position in shares of SIGA Technologies during the first quarter valued at about $111,000. 55.40% of the stock is currently owned by institutional investors.

SIGA Technologies Stock Down 1.4 %

SIGA opened at $7.88 on Wednesday. SIGA Technologies, Inc. has a 52-week low of $4.26 and a 52-week high of $12.83. The company has a market cap of $562.40 million, a P/E ratio of 7.16 and a beta of 0.91. The firm’s 50-day moving average price is $9.04 and its 200-day moving average price is $8.27.

SIGA Technologies (NASDAQ:SIGA) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.03 earnings per share (EPS) for the quarter. SIGA Technologies had a net margin of 48.55% and a return on equity of 51.40%. The firm had revenue of $21.81 million for the quarter. During the same quarter last year, the company earned ($0.04) EPS. On average, research analysts anticipate that SIGA Technologies, Inc. will post 1.01 EPS for the current fiscal year.

SIGA Technologies Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.